Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Battle of the lenses: which contact lens best fights childhood nearsightedness?

NCT ID NCT06148870

Disease control Sponsor: Essilor International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests two different contact lenses designed to slow down the progression of myopia (nearsightedness) in children aged 6 to 11. Each child wears one type of lens on each eye for six months, then switches, so researchers can compare how well each lens controls eye growth and vision changes over a year. The goal is to find which lens is more effective at preventing eyesight from getting worse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
special contact lenses (myopia control lenses)
What this could lead to
If one lens works better, it could offer a more effective way to slow down worsening nearsightedness in children, reducing their need for stronger glasses.
What could go wrong
This is a small, early-stage trial with only 50 children, so results may not apply to everyone. The lenses might not slow myopia significantly or could cause discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Nov 2023

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 11 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Volunteer subject and guardian, fluent English spoken, willing to follow protocol and able to read, comprehend and sign the informed consent \& assent form. * Equal to or greater than 6 years and not older than 11 years at time of informed consent and assent. * Spherical equivalent refractive error (SER) by manifest refraction between -0.50 and -4.75 D in each eye. * Astigmatism, if present, of not more than 2.00 D. * Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D. * Best corrected visual acuity in each eye better than +0.20 logMAR * Agree to wear study spectacles for at least 10 hours a day and 6 days a week * Willingness and ability to participate in trial for 1 year * Willingness and ability to attend scheduled visits * Not to involve concurrently in other myopia control treatments Exclusion Criteria: * History or presence of an Ocular disease, Strabismus, Amblyopia * Undergoing any myopia control intervention specifically Atropine and Orthokeratology * History of myopia control intervention specifically Atropine, Orthokeratology

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

eye disorder myopia refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia

Contacts and locations

Locations

  • Essilor R&D Centre Singapore

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.